# ProAssurance Corporation (PRA) — Financial Analysis

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-29  
**Tier:** Free primer (step 2 of 19)  
**Sibling pages:** /stocks/PRA/thesis · /stocks/PRA/memo

## Financial Snapshot

---
source: coverage-next-full | ticker: PRA | step: "04" | created: 2026-05-29
---

### Step 04 — Financial Snapshot: ProAssurance Corporation (PRA)

#### Income Statement Summary (FY2021–FY2025)

| $ Millions | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|------------|--------|--------|--------|--------|--------|
| Net Premiums Earned | ~$700M | ~$790M | ~$810M | ~$815M | ~$810M |
| Net Investment Income | ~$100M | ~$115M | ~$135M | ~$150M | ~$155M |
| Total Revenues | ~$825M | ~$915M | ~$975M | ~$995M | ~$1,020M |
| Losses & LAE | ~$590M | ~$680M | ~$690M | ~$685M | ~$680M |
| Operating Expenses | ~$215M | ~$235M | ~$245M | ~$250M | ~$255M |
| Pretax Income | ~$20M | ~$0M | ~$40M | ~$60M | ~$85M |
| Net Income | ~$15M | ~$(10)M | ~$30M | ~$45M | ~$65M |
| Diluted EPS | ~$0.30 | ~$(0.20) | ~$0.60 | ~$0.90 | ~$1.30 |
| Dividends per Share | $0.31 | $0.31 | $0.31 | $0.31 | $0.31 |

Notes:
- FY2021: First full year post-NORCAL acquisition; integration and reserve strengthening drag
- FY2022: Net loss driven by social inflation reserve strengthening, particularly long-term care lines
- FY2023-2025: Gradual improvement as rate actions take hold and investment income recovers
- Dividend maintained at $0.31/year throughout despite period of losses — signal of capital discipline and management confidence in reserve trajectory

#### Combined Ratio by Segment

| Segment | FY2022 | FY2023 | FY2024 | FY2025 |
|---------|--------|--------|--------|--------|
| **Specialty P&C** | ~115% | ~112% | ~108% | ~104% |
| **Workers' Comp** | ~96% | ~95% | ~95% | ~96% |
| **Lloyd's Syndicates** | ~100% | ~98% | ~97% | ~96% |
| **Consolidated** | ~110% | ~107% | ~104% | ~101% |

Key Observation: The Specialty P&C segment has run a combined ratio above 100% for each of FY2022–FY2025, meaning every dollar of premium earned generated an underwriting loss. The economics of the consolidated company have only been viable due to:
1. Net investment income (~$155M/year)
2. Favorable workers' comp profitability
3. Gradual improvement in Lloyd's results

#### Components of Specialty P&C Combined Ratio (FY2025 estimate)

| Component | Ratio |
|-----------|-------|
| Loss Ratio | ~75–78% |
| LAE Ratio | ~8–10% |
| Expense Ratio | ~20–22% |
| **Combined Ratio** | **~104%** |

The loss ratio remains elevated versus the long-run target of ~65–70% for MPL due to:
- Social inflation in hospital and long-term care lines
- NORCAL reserve development (legacy claims-made tails)
- Claims severity inflation in obstetrics and neurosurgery

#### Balance Sheet Highlights (FY2021–FY2025)

| $ Millions | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|------------|--------|--------|--------|--------|--------|
| Total Investments | ~$3,200M | ~$3,100M | ~$3,200M | ~$3,400M | ~$3,500M |
| Total Assets | ~$4,200M | ~$4,100M | ~$4,100M | ~$4,000M | ~$4,000M |
| Insurance Reserves | ~$2,600M | ~$2,700M | ~$2,700M | ~$2,700M | ~$2,650M |
| Long-Term Debt | ~$325M | ~$325M | ~$325M | ~$275M | ~$250M |
| Shareholders' Equity | ~$1,150M | ~$850M | ~$900M | ~$940M | ~$950M |
| Book Value per Share | ~$23 | ~$17 | ~$18 | ~$19 | ~$19 |
| Tangible Book Value/Share | ~$19 | ~$14 | ~$15 | ~$16 | ~$17 |

Notes:
- FY2022 equity drop: combined effect of net loss + unrealized investment losses on bond portfolio (rate rise impact)
- FY2023–2025: Gradual equity recovery; AOCI improvement as rates stabilize
- Long-term debt reduction: PRA retired ~$75M of senior notes between FY2022–FY2025
- Book value per share meaningfully below the $25.00 acquisition price (~1.3x P/BV) — validates strategic value premium over standalone intrinsic value

#### EPS Analysis

| Year | Diluted EPS | DPS | Payout Ratio |
|------|-------------|-----|--------------|
| FY2021 | $0.30 | $0.31 | >100% |
| FY2022 | $(0.20) | $0.31 | NM |
| FY2023 | $0.60 | $0.31 | 52% |
| FY2024 | $0.90 | $0.31 | 34% |
| FY2025 | $1.30 | $0.31 | 24% |

The improving EPS trajectory reflects: (a) rate increases flowing through earned premium, (b) investment income growth, and (c) modestly improving loss ratios. The payout ratio declined sharply as earnings recovered — at FY2025 run rates, PRA is generating meaningful earnings despite ongoing Specialty P&C underwriting losses.

#### Key Valuation Metrics (Pre-Announcement Baseline)

| Metric | FY2024 | FY2025 |
|--------|--------|--------|
| Price / Book Value | ~0.9x (pre-deal) | ~1.0x (pre-deal) |
| Price / Tangible Book | ~1.1x (pre-deal) | ~1.1x (pre-deal) |
| P/E (trailing) | ~15x | ~10x |
| Dividend Yield | ~3.5% | ~3.2% |
| Acquisition Price / BV | ~1.3x | ~1.3x |
| Acquisition Price / TBV | ~1.5x | ~1.5x |

The TDC offer represents a ~30% premium over pre-announcement trading levels, reflecting the strategic (not just financial) value of PRA's MPL franchise.

#### Important Caveat: Q1 2026 Update

Q1 2026 (10-Q filed May 5, 2026):
- Net premiums earned: ~$205M (annualized ~$820M)
- Net investment income: ~$40M (annualized ~$160M)
- Combined ratio guidance holding at ~100–103% for full year
- No material reserve development announced
- Merger on track for Q2/Q3 2026 close

#### Financial Quality Assessment

| Dimension | Rating | Notes |
|-----------|--------|-------|
| Revenue quality | Medium-High | Premiums durable; rate adequacy uncertain |
| Earnings quality | Medium | Investment income masking underwriting losses |
| Balance sheet | Medium-High | Investments high-quality; reserve risk the key uncertainty |
| Earnings trend | Improving | Loss ratio improving from 2022 nadir |
| Capital adequacy | Adequate | RBC ratios above regulatory minimums |
| Reserve adequacy | Uncertain | Social inflation creates ongoing adverse development risk |

The financial profile is that of a specialty insurer in the late stages of a difficult underwriting cycle. Results are improving, but the company was acquired before it could demonstrate a sustained return to normalized (~98%) combined ratios.

## Deeper Financial Analysis

The fundamental tier ($1.00) adds 8 dimensions not included here:

- Revenue Breakdown — segment revenue, geographic mix, product-line margins
- Financial Trends — QoQ momentum, leading indicators, inflection points
- Balance Sheet — debt structure, dilution risk, working capital dynamics
- Capital Allocation — ROIC, buyback cadence, reinvestment efficiency
- Earnings Analysis — beats/misses, guidance vs actuals, transcript highlights
- Competitive Positioning — market share, pricing power, peer benchmarks
- Industry Context — TAM, sector tailwinds/headwinds, regulatory backdrop

**API endpoint:** GET /api/v1/research/PRA/fundamental

## Navigation

- Overview: /stocks/PRA
- Financials (this page): /stocks/PRA/financials
- Thesis: /stocks/PRA/thesis
- Investment Memo: /stocks/PRA/memo
- Coverage universe: /stocks